Loading…

Synektik SASNT.WACompetitor analysis, valuation and peers

Poland · PLN·Health Care›Medical Specialties
Momentum neutral 47
Mkt cap
$713M
US dollars, full cap
Free float
60%
of shares outstanding
$/day
$2.27M
20-day average traded
Fwd P/E
11.8×
forward earnings
ROIC−WACC
+93.0 pp
WACC 10.0%
Hurdle
-40 pp
Req g minus delivered
Next earnings
26 days
2 Dec 2026
Close · PLNPLN 327.80
1D+1.9%
1W+0.2%
1M-4.4%
3M-10.5%
6M+16.3%
YTD+30.6%
1Y+39.3%
ATR %3.2%
52w lowhigh17.7% off high

What Synektik does

No business profile yet.

Synektik at a glance

Size Synektik (SNT.WA) is a Poland Health Care company (Medical Specialties) with a market value of $713M, the 50th largest of 83 Poland companies the cockpit tracks. Shares closed at PLN 327.80 on 6 Nov 2026.

Performance Over six months the shares gained 16.3%, against -9.0% for the median peer and +14.3% for the Poland market (cap-weighted) — 5th highest of 21 in its peer set.

Growth Revenue grew 49.7% over the last twelve months (peer median +5.9%); the operating margin is 24.1% (peer median 11.0%).

Valuation It trades at 11.8× forward earnings against a peer median of 20.0× (3rd cheapest of 17).

Price implies For today's price to make sense, revenue must grow about 0% a year for seven years (Req g). Recent delivered growth is +40%, so the hurdle is -40 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 93.0 points above its cost of capital (10.0% WACC).

Next results Next results expected around 2 Dec 2026 (exchange calendar; dates can move).

Relative performance

8010012014011 May 202611 Aug 20266 Nov 2026SNT.WA 117Peer median 91
Six months, rebased to 100: Synektik against the median of its 20 peers (local-currency closes).

Synektik financials

Reported figures in PLN; fiscal year ends 2025-09-30. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenuePLN 933MPLN 682MPLN 624MPLN 447MPLN 167M
Revenue growth—+9%+40%+168%—
Gross profitPLN 327MPLN 244MPLN 190MPLN 132MPLN 48.5M
EBITDAPLN 246MPLN 179MPLN 143MPLN 84.0MPLN 20.6M
Net incomePLN 417MPLN 103MPLN 82.6MPLN 52.5MPLN 10.3M
Free cash flowPLN 154MPLN 58.6MPLN 43.3MPLN 84.8M-PLN 17.7M
Capital expenditurePLN 22.1MPLN 17.4MPLN 44.9MPLN 9.68MPLN 10.2M
Total debtPLN 41.5MPLN 40.9MPLN 24.5MPLN 18.7MPLN 36.9M

Quarterly statements and history in the cockpit →

Synektik competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-20%0%+20%+40%+60%-10%0%+10%MLAB491000688410PACB688085002876300326QDEL3004537575688236300952688389301234300622CTKB1789INMD301367VREXSNT.WA6-month return →1-month return →
Up and to the right = strong over both horizons. Synektik is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%+40%20×40×MLAB688410688085002876300326QDEL30045375756882363009526883893006221789INMD301367VREXSNT.WARevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Synektik is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%MLAB68841068808500287630032630045375756882366883893012343006221789INMD301367SNT.WAGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Synektik is the large dot.

Synektik competitors and peer comparison

How Synektik compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Synektik against its 20 peers (data as of 6 Nov 2026)
MeasureSNT.WAPeer medianRank in peer set
1-month return-4.4%+0.5%6th lowest of 21
6-month return+16.3%-9.0%5th highest of 21
Distance from 52-week high-17.7%-25.6%7th highest of 21
Revenue growth (TTM)+49.7%+5.9%2nd highest of 21
Operating margin24.1%11.0%3rd highest of 21
Forward P/E11.8×20.0×3rd cheapest of 17
Growth the price implies (Req g, 7 yrs)0.1%4.1%8th least demanding of 15
Growth delivered (Del g)+40.3%+12.1%highest of 15
Hurdle (Req g minus delivered)-40.2 pp-8.4 ppleast demanding of 15
ROIC minus cost of capital+93.0 pp+2.5 pphighest of 21
EV / EBITDA11.2×8.4×2nd most expensive of 7
Net debt / EBITDA-0.1×1.1×4th least indebted of 7

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Synektik SNT.WAPoland$713M+16%+50%24%11.8×0.1%+40.3%
Mesa Laboratories MLABUnited States$718M+23%+3%9%12.6×21.1%+13.2%
Livsmed 491000.KSSouth Korea$706M-47%+89%-59%n/an/an/a
SWS Hemodialysis Care 688410.SSChina$723M-12%+31%19%24.1×16.7%+25.9%
Pacific Biosciences of California PACBUnited States$701M+60%+2%-102%n/an/an/a
Shanghai Sanyou Medical 688085.SSChina$700M-21%+15%4%50.9×29.1%+6.8%
Shenzhen Sunnypol Optoelectornics 002876.SZChina$728M-8%+29%5%41.8×11.1%+14.2%
Shanghai Kinetic Medical 300326.SZChina$698M-7%-28%17%27.4×8.1%-1.9%
QuidelOrtho QDELUnited States$734M-1%-5%-2%12.0×n/an/a
Jiang Xi Sanxin Medtec 300453.SZChina$741M-5%+12%18%16.1×-2.1%+11.8%
Japan Lifeline 7575.TJapan$685M+16%+6%19%14.1×-9.7%+2.9%
Beijing Chunlizhengda Medical Instruments 688236.SSChina$684M-21%-13%31%19.1×-5.4%+2.2%
Jiangsu Hanvo Safety Product 300952.SZChina$681M-21%+6%8%47.6×n/an/a
Shenzhen Lifotronic Technology 688389.SSChina$749M-11%+14%13%32.4×13.5%+13.3%
Anhui Hongyu Wuzhou Medical Manufacturer 301234.SZChina$750M+177%-14%3%n/a33.5%-0.6%
Doctorglasses Chain 300622.SZChina$757M-10%+6%14%24.5×-2.4%+15.7%
Cytek Biosciences CTKBUnited States$758M+26%+5%-22%n/an/an/a
AK Medical 1789.HKHong Kong$664M-26%+16%26%10.8×-11.4%+6.7%
InMode INMDUnited States$767M-5%-7%18%10.1×-10.5%+12.4%
BMC Medical 301367.SZChina$780M-13%+37%17%19.8×0.1%+15.6%
Varex Imaging VREXUnited States$783M-10%+5%8%20.3×n/an/a

Questions

Which companies are Synektik's closest peers?
The cockpit's peer set: Mesa Laboratories (MLAB), Livsmed (491000.KS), SWS Hemodialysis Care (688410.SS), Pacific Biosciences of California (PACB), Shanghai Sanyou Medical (688085.SS), Shenzhen Sunnypol Optoelectornics (002876.SZ), Shanghai Kinetic Medical (300326.SZ), QuidelOrtho (QDEL).
Is Synektik expensive compared with its peers?
On forward p/e it trades at 11.8× against a peer median of 20.0×, 3rd cheapest of 17 in its peer set. For today's price to make sense, revenue must grow about 0% a year for seven years (Req g). Recent delivered growth is +40%, so the hurdle is -40 pp: the price already allows for a slowdown.
How has Synektik stock performed?
Over six months to 6 Nov 2026 the shares returned +16.3% against -9.0% for the median peer; over one year +39.3%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.